SK506785A3 - Method for isolation of human necrosis factor (tnf), human tnf, a mixture containing tnf, a variant of tnf, dna coding tnf, a cell trasnsformed with dna and pharmaceutical composition - Google Patents

Method for isolation of human necrosis factor (tnf), human tnf, a mixture containing tnf, a variant of tnf, dna coding tnf, a cell trasnsformed with dna and pharmaceutical composition Download PDF

Info

Publication number
SK506785A3
SK506785A3 SK5067-85A SK506785A SK506785A3 SK 506785 A3 SK506785 A3 SK 506785A3 SK 506785 A SK506785 A SK 506785A SK 506785 A3 SK506785 A3 SK 506785A3
Authority
SK
Slovakia
Prior art keywords
tumor necrosis
necrosis factor
tnf
dna
human
Prior art date
Application number
SK5067-85A
Other languages
English (en)
Slovak (sk)
Other versions
SK279897B6 (sk
Inventor
Bharat B Aggarwal
David V Goeddel
Sang He Lee
Glenn E Nedwin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/677,257 external-priority patent/US4650674A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SK506785A3 publication Critical patent/SK506785A3/sk
Publication of SK279897B6 publication Critical patent/SK279897B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
SK5067-85A 1984-07-05 1985-07-05 Spôsob izolácie ľudského nekrotizujúceho faktora ( SK279897B6 (sk)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62795984A 1984-07-05 1984-07-05
US62806084A 1984-07-05 1984-07-05
US62805984A 1984-07-05 1984-07-05
US67745484A 1984-12-03 1984-12-03
US67715684A 1984-12-03 1984-12-03
US06/677,257 US4650674A (en) 1984-07-05 1984-12-03 Synergistic cytotoxic composition

Publications (2)

Publication Number Publication Date
SK506785A3 true SK506785A3 (en) 1999-05-07
SK279897B6 SK279897B6 (sk) 1999-05-07

Family

ID=27560190

Family Applications (1)

Application Number Title Priority Date Filing Date
SK5067-85A SK279897B6 (sk) 1984-07-05 1985-07-05 Spôsob izolácie ľudského nekrotizujúceho faktora (

Country Status (20)

Country Link
EP (1) EP0168214B1 (da)
JP (4) JP2557341B2 (da)
AT (1) ATE113295T1 (da)
AU (1) AU599571B2 (da)
BG (1) BG60250B2 (da)
CZ (1) CZ283149B6 (da)
DE (2) DE3587939T2 (da)
DK (2) DK169894B1 (da)
FI (2) FI95472C (da)
GR (1) GR851626B (da)
HU (1) HU209153B (da)
IE (1) IE65426B1 (da)
IL (2) IL75717A (da)
LU (1) LU90456I2 (da)
NL (1) NL990033I2 (da)
NO (1) NO852673L (da)
NZ (1) NZ212632A (da)
PL (1) PL155778B1 (da)
SK (1) SK279897B6 (da)
YU (1) YU47968B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
EP0155549B1 (en) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
EP0216786B1 (en) * 1984-12-21 1992-03-18 Biogen, Inc. Purification, production and use of tumor necrosis factors
JPS61155330A (ja) * 1984-12-28 1986-07-15 Denichi Mizuno 蛋白質標品
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
DE3750915T2 (de) * 1986-02-04 1995-08-24 Den Ichi Mizuno Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe.
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
JPH0817712B2 (ja) * 1986-06-20 1996-02-28 大日本製薬株式会社 新規ヒトｔｎｆポリペプチド変異体
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US4857314A (en) * 1986-07-18 1989-08-15 Health Research , Inc. C-reactive proteins in treatment of animal and human cancers
CA1340698C (en) * 1986-07-25 1999-08-10 Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo Preparation and uses of interferon-gamma
IE59814B1 (en) * 1986-07-31 1994-04-06 Genentech Inc Method and composition for the prophylaxis and treatment of retroviral infections
US5002876A (en) * 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
EP0750037A3 (en) 1989-08-16 1997-01-15 Cetus Oncology Corporation TNF-convertase and method measuring inhibition of TNF convertase
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
JP3241041B2 (ja) * 1990-03-12 2001-12-25 ペプテック リミテッド 好中球刺激ペプチド
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
IL120979A0 (en) * 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH65623A (de) * 1913-08-02 1914-07-01 Siemens Ag Zeitrelais mit Wechselstrommotor und dessen Drehmoment entgegenwirkender Feder
NO163060C (no) * 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS60226816A (ja) * 1984-11-16 1985-11-12 Asahi Chem Ind Co Ltd 抗腫瘍活性をもつヒト由来蛋白質
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
JPS60166696A (ja) * 1984-02-08 1985-08-29 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄνａ
JPS60221092A (ja) * 1984-04-18 1985-11-05 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドのｄｎａ
EP0148311B1 (en) * 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha A novel physiologically active polypeptide
JPS60137292A (ja) * 1983-12-26 1985-07-20 Asahi Chem Ind Co Ltd 新規生理活性ポリペプチドの遺伝情報を有するポリデオキシリボ核酸、該ポリデオキシリボ核酸を含む複製可能な組換ｄνａ、該複製可能な組換ｄνａで形質転換された微生物または細胞、新規生理活性ポリペプチド及びその製造方法
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
JPS60232097A (ja) * 1984-04-23 1985-11-18 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子ポリペプチドの製造法
EP0155549B1 (en) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
JP2515975B2 (ja) * 1985-02-26 1996-07-10 大日本製薬株式会社 抗腫瘍作用を有するポリペプチド

Also Published As

Publication number Publication date
HU209153B (en) 1994-03-28
DK169894B1 (da) 1995-03-27
PL254399A1 (en) 1986-06-17
DE3587939T2 (de) 1995-04-27
JPS6140221A (ja) 1986-02-26
ATE113295T1 (de) 1994-11-15
GR851626B (da) 1985-11-26
FI95472B (fi) 1995-10-31
FI98217B (fi) 1997-01-31
FI943750A0 (fi) 1994-08-15
BG60250B1 (bg) 1994-03-24
FI852626A0 (fi) 1985-07-03
BG60250B2 (bg) 1994-03-24
EP0168214A3 (en) 1987-12-16
DK75694A (da) 1994-06-24
DE19975064I2 (de) 2005-11-03
FI98217C (fi) 1997-05-12
CZ283149B6 (cs) 1998-01-14
HUT38125A (en) 1986-04-28
JPH0928387A (ja) 1997-02-04
IE65426B1 (en) 1995-11-01
AU4465285A (en) 1986-01-09
YU47968B (sh) 1996-08-13
FI852626L (fi) 1986-01-06
IL75717A0 (en) 1985-11-29
IL75717A (en) 1994-11-28
FI95472C (fi) 1996-02-12
CZ506785A3 (en) 1997-07-16
DK305885D0 (da) 1985-07-04
YU113285A (en) 1991-04-30
EP0168214B1 (en) 1994-10-26
JP2557341B2 (ja) 1996-11-27
LU90456I2 (fr) 1999-12-06
NO852673L (no) 1986-01-06
JPH083061A (ja) 1996-01-09
FI943750A (fi) 1994-08-15
NL990033I1 (nl) 1999-12-01
IE851691L (en) 1986-01-05
EP0168214A2 (en) 1986-01-15
SK279897B6 (sk) 1999-05-07
IL105271A (en) 1995-07-31
NZ212632A (en) 1991-05-28
JP2614989B2 (ja) 1997-05-28
DE3587939D1 (de) 1994-12-01
PL155778B1 (pl) 1992-01-31
DK305885A (da) 1986-03-14
NL990033I2 (nl) 2000-11-01
DK171418B1 (da) 1996-10-21
JPH07291997A (ja) 1995-11-07
AU599571B2 (en) 1990-07-26
DE19975064I1 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
SK506785A3 (en) Method for isolation of human necrosis factor (tnf), human tnf, a mixture containing tnf, a variant of tnf, dna coding tnf, a cell trasnsformed with dna and pharmaceutical composition
US4650674A (en) Synergistic cytotoxic composition
FI93025B (fi) Rekombinantti lymfotoksiini
HU208710B (en) Method for preparation of mammalian human il-4, dna encoding il-4, host cell and pharmaceutical composition comprising human il-4
US5683688A (en) Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US6686455B1 (en) Tumor necrosis factor
KR930010767B1 (ko) 종양 괴사 인자
PT80758B (pt) Metodo para a preparacao de factor de necrose tumoral
IL104297A (en) Lymphotoxin Nucleic acid encoding vectors containing the nucleic acid and cells converted by them Methods for obtaining lymphotoxin
NZ226980A (en) Lymphotoxin-neutralising antibody and its use in separating out lymphotoxin from a composition

Legal Events

Date Code Title Description
SPCE Expiry of an spc

Free format text: PRODUCT NAME: TASONERMIN; REG.NO./DATE: EU/1/99/097/001, 19990413

Spc suppl protection certif: 33 5006-2004

Filing date: 20041029

Extension date: 20100706